Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.

Open-Label, Single-Arm, Multicenter, Pharmacokinetic, Safety, and Efficacy Study of Adjunctive Administration of Brivaracetam in Subjects From ≥1 Month to <16 Years Old With Epilepsy

Initial study in children with epilepsy to evaluate the pharmacokinetics, safety, tolerability and preliminary efficacy of adjunctive treatment with brivaracetam, and to develop dosing adaptations for future studies.

Inclusion Criteria:

• Clinical diagnosis of epilepsy
• Subject having at least 1 seizure (any type) during the 3 weeks before first visit
• Stable dosing of 1-3 concomitant antiepileptic drugs

Exclusion Criteria:

• Pregnant or nursing females
• Concomitant use of Levetiracetam
• Epilepsy secondary to a Progressive cerebral disease/tumor or other neurodegenerative disease
• History of status epilepticus
• Clinically significant acute or chronic illness, underlying disease or medication condition
• History of suicide attempt